Protective effect of lipid microspheres 1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris: A pilot study

Journal of Cardiovascular Medicine

Volumn 12, Issue 11, 2011, Pages 790-794

  Luo, Chu Fan ^a   Wu, Xing ^b   Hu, Xun ^b   Wu, Gui Fu ^b   Hu, Cheng Heng ^b   Du, Zhi Min ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b NONE

Author keywords

Angina pectoris; Cardiac troponin T; Creatine kinase MB; Percutaneous coronary intervention; Prostaglandin E1 incorporated into lipid microspheres

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MICROSPHERE; PROSTAGLANDIN E1; TROPONIN T;

ADULT; ARTICLE; BLOOD LEVEL; CARDIAC PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; INCIDENCE; LABORATORY TEST; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

AGED; ALPROSTADIL; ANALYSIS OF VARIANCE; ANGINA PECTORIS; ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ANGIOGRAPHY; CREATINE KINASE, MB FORM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 80053589773     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834bb47c     Document Type: Article

References (24)

1. Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome. Ann Clin Biochem 2002; 39:392-397 (Pubitemid 34743641)
2. Herrmann J, Von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002; 87:549-553 (Pubitemid 34547979)
3. Schiano P, Gabriel Steg P. Measurement and prevention of myocardial injury during percutaneous coronary intervention. Heart 2007; 93:656-657 (Pubitemid 46808259)
4. Heidrich H, Schmidt T, Fahrig C. Are there predictors for the outcome of a PGE1 treatment in peripheral arterial disease with critical limb ischaemia? Vasa 2005; 34:101-107 (Pubitemid 40825773)
5. Miyata T, Yamada N, Miyachi Y. Efficacy by ulcer type and safety of lipo- PGE1 for Japanese patients with diabetic foot ulcers. J Atheroscler Thromb 2010; 17:805-816
6. Matsuo H, Shigematsu H. Patient-based outcomes using the Walking Impairment Questionnaire for patients with peripheral arterial occlusive disease treated with Lipo-PGE1. Circ J 2010; 74:365-370.
7. Siegel RJ, Shah PK, Nathan M, Rodriguez L, Shell WE. Prostaglandin E1 infusion in unstable angina: effects on anginal frequency and cardiac function. Am Heart J 1984; 108:863-868 (Pubitemid 14015510)
8. Shechter M, Agranat O, Har-Zahav Y, Rath S, Kaplinsky E, Rabinowitz B. Prostaglandin E1 during angioplasty as preventive therapy for coronary restenosis. Am J Ther 1997; 4:395-400 (Pubitemid 27508003)
9. Kastrati A, Neumann FJ, Mehilli J, Ferns GA. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688-696
10. Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010; 31:582-587
11. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40:1366-1374
12. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116:2634-2653 (Pubitemid 350182388)
13. Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Minor myocardial injury after elective uncomplicated successful PTCA with or without stenting: detection by cardiac troponins. Catheter Cardiovasc Interv 2001; 53:188-192 (Pubitemid 32532178)
14. Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114:662-669 (Pubitemid 44252308)
15. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26:2493-2519 (Pubitemid 41679359)
16. Thel MC, Califf RM, Tardiff BE, et al. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol 2000; 85:427-434 (Pubitemid 30089616)
17. Miller WL, Garratt KN, Burritt MF, Reeder GS, Jaffe AS. Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. Chest 2004; 125:275-280 (Pubitemid 38114592)
18. Stanek B, Pacher R. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure. Jpn Heart J 1997; 38:53-65 (Pubitemid 27136224)
19. Hülsmann M, Stanek B, Frey B, et al. Hemodynamic and neurohum oral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure. J Heart Lung Transplant 1997; 16:556-562 (Pubitemid 27287787)
20. Hide EJ, Ney P, Piper J, Thiemermann C, Vane JR. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol 1995; 116:2435-2440
21. Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation 1995; 92:935-943
22. Huk I, Brovkovych V, Nanobashvili J, et al. Prostaglandin E1 reduces ischemia/reperfusion injury by normalizing nitric oxide and superoxide release. Shock 2000; 14:234-242
23. Kawamura T, Nara N, Kadosaki M, Inada K, Endo S. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med 2000; 28:2201-2208 (Pubitemid 30604416)
24. Fox SC, Behan MW, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35:39-46 (Pubitemid 38054787)